Endogenous retroviruses and the development of cancer

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1343-1349

  Kassiotis, George ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN;

CANCER IMMUNOTHERAPY; CHROMOSOME REARRANGEMENT; DISEASE ASSOCIATION; ENDOGENOUS RETROVIRUS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; GENETIC VARIABILITY; GERM CELL TUMOR; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LONG TERMINAL REPEAT; MELANOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; RNA TRANSCRIPTION; VIRUS ACTIVATION; VIRUS CARCINOGENESIS; VIRUS EXPRESSION; VIRUS REPLICATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENDOGENOUS RETROVIRUSES; HUMANS; MICE; NEOPLASMS; RETROVIRIDAE INFECTIONS; RETROVIRIDAE PROTEINS; TUMOR VIRUS INFECTIONS;

EID: 84896703728     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302972     Document Type: Review

References (90)

1. Dewannieux, M. and T. Heidmann. 2013. Endogenous retroviruses: acquisition, amplification and taming of genome invaders. Curr. Opin. Virol. 3: 646-656. doi: 10.1016/j.coviro.2013.08.005.
2. Feschotte, C., and C. Gilbert. 2012. Endogenous viruses: insights into viral evolution and impact on host biology. Nat. Rev. Genet. 13: 283-296.
3. Stoye, J. P. 2012. Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat. Rev. Microbiol. 10: 395-406.
4. Stocking, C., and C. A. Kozak. 2008. Murine endogenous retroviruses. Cell. Mol. Life Sci. 65: 3383-3398.
5. Magiorkinis, G., R. J. Gifford, A. Katzourakis, J. De Ranter, and R. Belshaw. 2012. Env-less endogenous retroviruses are genomic superspreaders. Proc. Natl. Acad. Sci. USA 109: 7385-7390.
6. Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh, et al International Human Genome Sequencing Consortium. 2001. Initial sequencing and analysis of the human genome. [Published erratum appears in 2001 Nature 411: 720; 2001 Nature 412: 565.] Nature 409: 860-921.
7. Waterston, R. H., K. Lindblad-Toh, E. Birney, J. Rogers, J. F. Abril, P. Agarwal, R. Agarwala, R. Ainscough, M. Alexandersson, P. An, et al Mouse Genome Sequencing Consortium. 2002. Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-562.
8. Burns, K. H., and J. D. Boeke. 2012. Human transposon tectonics. Cell 149: 740-752.
9. Kramerov, D. A., and N. S. Vassetzky. 2011. SINEs. Wiley Interdiscip. Rev. RNA 2: 772-786.
10. Blomberg, J., F. Benachenhou, V. Blikstad, G. Sperber, and J. Mayer. 2009. Classification and nomenclature of endogenous retroviral sequences (ERVs): problems and recommendations. Gene 448: 115-123.
11. Weiss, R. A. 2013. On the concept and elucidation of endogenous retroviruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368: 20120494.
12. Belshaw, R., A. L. Dawson, J. Woolven-Allen, J. Redding, A. Burt, and M. Tristem. 2005. Genomewide screening reveals high levels of insertional polymorphism in the human endogenous retrovirus family HERV-K(HML2): implications for presentday activity. J. Virol. 79: 12507-12514.
13. Hancks, D. C., and H. H. Kazazian, Jr. 2012. Active human retrotransposons: variation and disease. Curr. Opin. Genet. Dev. 22: 191-203.
14. Subramanian, R. P., J. H. Wildschutte, C. Russo, and J. M. Coffin. 2011. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology 8: 90.
15. Goodier, J. L., and H. H. Kazazian, Jr. 2008. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell 135: 23-35.
16. Cardiff, R. D., and N. Kenney. 2011. A compendium of the mouse mammary tumor biologist: from the initial observations in the house mouse to the development of genetically engineered mice. Cold Spring Harb. Perspect. Biol. 3(6).
17. Weiss, R. A. 2006. The discovery of endogenous retroviruses. Retrovirology 3: 67.
18. Moore, P. S., and Y. Chang. 2010. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer 10: 878-889.
19. Shimkin, M. B. 1975. A. E. C. Lathrop (1868-1918): Mouse Woman of Granby. Cancer Res. 35: 1597-1598.
20. Crow, J. F. 2002. C. C. Little, cancer and inbred mice. Genetics 161: 1357-1361.
21. Maksakova, I. A., M. T. Romanish, L. Gagnier, C. A. Dunn, L. N. van de Lagemaat, and D. L. Mager. 2006. Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet. 2: e2.
22. Stoye, J. P., S. Fenner, G. E. Greenoak, C. Moran, and J. M. Coffin. 1988. Role of endogenous retroviruses as mutagens: the hairless mutation of mice. Cell 54: 383-391.
23. Yalcin, B., K. Wong, A. Agam, M. Goodson, T. M. Keane, X. Gan, C. Nellåker, L. Goodstadt, J. Nicod, A. Bhomra, et al. 2011. Sequence-based characterization of structural variation in the mouse genome. Nature 477: 326-329.
24. Jenkins, N. A., N. G. Copeland, B. A. Taylor, and B. K. Lee. 1981. Dilute (d) coat colour mutation of DBA/2J mice is associated with the site of integration of an ecotropic MuLV genome. Nature 293: 370-374.
25. Ruprecht, K., J. Mayer, M. Sauter, K. Roemer, and N. Mueller-Lantzsch. 2008. Endogenous retroviruses and cancer. Cell. Mol. Life Sci. 65: 3366-3382.
26. Young, G. R., J. P. Stoye, and G. Kassiotis. 2013. Are human endogenous retroviruses pathogenic? An approach to testing the hypothesis. Bioessays 35: 794-803.
27. Fan, H., and C. Johnson. 2011. Insertional oncogenesis by non-acute retroviruses: implications for gene therapy. Viruses 3: 398-422.
28. Voisset, C., R. A. Weiss, and D. J. Griffiths. 2008. Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol. Mol. Biol. Rev. 72: 157-196.
29. Lee, E., R. Iskow, L. Yang, O. Gokcumen, P. Haseley, L. J. Luquette, III, J. G. Lohr, C. C. Harris, L. Ding, R. K. Wilson, et al Cancer Genome Atlas Research Network. 2012. Landscape of somatic retrotransposition in human cancers. Science 337: 967-971.
30. Dewannieux, M., F. Harper, A. Richaud, C. Letzelter, D. Ribet, G. Pierron, and T. Heidmann. 2006. Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. Genome Res. 16: 1548-1556.
31. Lee, Y. N., and P. D. Bieniasz. 2007. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3: e10.
32. Hughes, J. F., and J. M. Coffin. 2005. Human endogenous retroviral elements as indicators of ectopic recombination events in the primate genome. Genetics 171: 1183-1194.
33. Contreras-Galindo, R., M. H. Kaplan, A. C. Contreras-Galindo, M. J. Gonzalez-Hernandez, I. Ferlenghi, F. Giusti, E. Lorenzo, S. D. Gitlin, M. H. Dosik, Y. Yamamura, and D. M. Markovitz. 2012. Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals. J. Virol. 86: 262-276.
34. Young, G. R., U. Eksmond, R. Salcedo, L. Alexopoulou, J. P. Stoye, and G. Kassiotis. 2012. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature 491: 774-778.
35. Yu, P., W. Lübben, H. Slomka, J. Gebler, M. Konert, C. Cai, L. Neubrandt, O. Prazeres da Costa, S. Paul, S. Dehnert, et al. 2012. Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERVinduced tumors. Immunity 37: 867-879.
36. Bénit, L., P. Dessen, and T. Heidmann. 2001. Identification, phylogeny, and evolution of retroviral elements based on their envelope genes. J. Virol. 75: 11709-11719.
37. Villesen, P., L. Aagaard, C. Wiuf, and F. S. Pedersen. 2004. Identification of endogenous retroviral reading frames in the human genome. Retrovirology 1: 32.
38. Ross, S. R. 2010. Mouse mammary tumor virus molecular biology and oncogenesis. Viruses 2: 2000-2012.
39. Tai, A. K., M. Lin, F. Chang, G. Chen, F. Hsiao, N. Sutkowski, and B. T. Huber. 2006. Murine Vbeta3+ and Vbeta7+ T cell subsets are specific targets for the HERV-K18 Env superantigen. J. Immunol. 177: 3178-3184.
40. Ebert, P. J., S. Jiang, J. Xie, Q. J. Li, and M. M. Davis. 2009. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat. Immunol. 10: 1162-1169.
41. Young, G. R., M. J. Ploquin, U. Eksmond, M. Wadwa, J. P. Stoye, and G. Kassiotis. 2012. Negative selection by an endogenous retrovirus promotes a higher-avidity CD4+ T cell response to retroviral infection. PLoS Pathog. 8: e1002709.
42. Baudino, L., K. Yoshinobu, N. Morito, M. L. Santiago-Raber, and S. Izui. 2010. Role of endogenous retroviruses in murine SLE. Autoimmun. Rev. 10: 27-34.
43. Kershaw, M. H., C. Hsu, W. Mondesire, L. L. Parker, G. Wang, W. W. Overwijk, R. Lapointe, J. C. Yang, R. F. Wang, N. P. Restifo, and P. Hwu. 2001. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 61: 7920-7924.
44. Sacha, J. B., I. J. Kim, L. Chen, J. H. Ullah, D. A. Goodwin, H. A. Simmons, D. I. Schenkman, F. von Pelchrzim, R. J. Gifford, F. A. Nimityongskul, et al. 2012. Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic. J. Immunol. 189: 1467-1479.
45. Oricchio, E., I. Sciamanna, R. Beraldi, G. V. Tolstonog, G. G. Schumann, and C. Spadafora. 2007. Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene 26: 4226-4233.
46. Galli, U. M., M. Sauter, B. Lecher, S. Maurer, H. Herbst, K. Roemer, and N. Mueller-Lantzsch. 2005. Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors. Oncogene 24: 3223-3228.
47. Dupressoir, A., C. Lavialle, and T. Heidmann. 2012. From ancestral infectious retroviruses to bona fide cellular genes: role of the captured syncytins in placentation. Placenta 33: 663-671.
48. Duelli, D., and Y. Lazebnik. 2003. Cell fusion: a hidden enemy? Cancer Cell 3: 445-448.
49. Bjerregaard, B., S. Holck, I. J. Christensen, and L. I. Larsson. 2006. Syncytin is involved in breast cancer-endothelial cell fusions. Cell. Mol. Life Sci. 63: 1906-1911.
50. Lavialle, C., G. Cornelis, A. Dupressoir, C. Esnault, O. Heidmann, C. Vernochet, and T. Heidmann. 2013. Paleovirology of 'syncytins', retroviral env genes exapted for a role in placentation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368: 20120507.
51. Mangeney, M., and T. Heidmann. 1998. Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc. Natl. Acad. Sci. USA 95: 14920-14925.
52. Mangeney, M., J. Pothlichet, M. Renard, B. Ducos, and T. Heidmann. 2005. Endogenous retrovirus expression is required for murine melanoma tumor growth in vivo. Cancer Res. 65: 2588-2591.
53. Pothlichet, J., T. Heidmann, and M. Mangeney. 2006. A recombinant endogenous retrovirus amplified in a mouse neuroblastoma is involved in tumor growth in vivo. Int. J. Cancer 119: 815-822.
54. Naito, T., H. Ogasawara, H. Kaneko, T. Hishikawa, I. Sekigawa, H. Hashimoto, and N. Maruyama. 2003. Immune abnormalities induced by human endogenous retroviral peptides: with reference to the pathogenesis of systemic lupus erythematosus. J. Clin. Immunol. 23: 371-376.
55. Mangeney, M., N. de Parseval, G. Thomas, and T. Heidmann. 2001. The fulllength envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties. J. Gen. Virol. 82: 2515-2518.
56. Jern, P., and J. M. Coffin. 2008. Effects of retroviruses on host genome function. Annu. Rev. Genet. 42: 709-732.
57. Cohen, C. J., W. M. Lock, and D. L. Mager. 2009. Endogenous retroviral LTRs as promoters for human genes: a critical assessment. Gene 448: 105-114.
58. Goldstone, D. C., V. Ennis-Adeniran, J. J. Hedden, H. C. Groom, G. I. Rice, E. Christodoulou, P. A. Walker, G. Kelly, L. F. Haire, M. W. Yap, et al. 2011. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480: 379-382.
59. Luban, J. 2012. Innate immune sensing of HIV-1 by dendritic cells. Cell Host Microbe 12: 408-418.
60. Atianand, M. K., and K. A. Fitzgerald. 2013. Molecular basis of DNA recognition in the immune system. J. Immunol. 190: 1911-1918.
61. Stetson, D. B., J. S. Ko, T. Heidmann, and R. Medzhitov. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587-598.
62. Landau, D. A., S. L. Carter, P. Stojanov, A. McKenna, K. Stevenson, M. S. Lawrence, C. Sougnez, C. Stewart, A. Sivachenko, L. Wang, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714-726.
63. Imielinski, M., A. H. Berger, P. S. Hammerman, B. Hernandez, T. J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, et al. 2012. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120.
64. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
65. Shav-Tal, Y., and D. Zipori. 2002. PSF and p54(nrb)/NonO - multi-functional nuclear proteins. FEBS Lett. 531: 109-114.
66. Li, L., T. Feng, Y. Lian, G. Zhang, A. Garen, and X. Song. 2009. Role of human noncoding RNAs in the control of tumorigenesis. Proc. Natl. Acad. Sci. USA 106: 12956-12961.
67. Faulkner, G. J., Y. Kimura, C. O. Daub, S. Wani, C. Plessy, K. M. Irvine, K. Schroder, N. Cloonan, A. L. Steptoe, T. Lassmann, et al. 2009. The regulated retrotransposon transcriptome of mammalian cells. Nat. Genet. 41: 563-571.
68. van de Lagemaat, L. N., J. R. Landry, D. L. Mager, and P. Medstrand. 2003. Transposable elements in mammals promote regulatory variation and diversification of genes with specialized functions. Trends Genet. 19: 530-536.
69. Conley, A. B., J. Piriyapongsa, and I. K. Jordan. 2008. Retroviral promoters in the human genome. Bioinformatics 24: 1563-1567.
70. Brown, C. J., S. Lain, C. S. Verma, A. R. Fersht, and D. P. Lane. 2009. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9: 862-873.
71. Wang, T., J. Zeng, C. B. Lowe, R. G. Sellers, S. R. Salama, M. Yang, S. M. Burgess, R. K. Brachmann, and D. Haussler. 2007. Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. Proc. Natl. Acad. Sci. USA 104: 18613-18618.
72. Lamprecht, B., K. Walter, S. Kreher, R. Kumar, M. Hummel, D. Lenze, K. Kochert, M. A. Bouhlel, J. Richter, E. Soler, et al. 2010. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat. Med. 16: 571-579, 1p following 579.
73. Tomlins, S. A., B. Laxman, S. M. Dhanasekaran, B. E. Helgeson, X. Cao, D. S. Morris, A. Menon, X. Jing, Q. Cao, B. Han, et al. 2007. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
74. Büscher, K., U. Trefzer, M. Hofmann, W. Sterry, R. Kurth, and J. Denner. 2005. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res. 65: 4172-4180.
75. Muster, T., A. Waltenberger, A. Grassauer, S. Hirschl, P. Caucig, I. Romirer, D. Födinger, H. Seppele, O. Schanab, C. Magin-Lachmann, et al. 2003. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 63: 8735-8741.
76. Dirksen, E. R., and J. A. Levy. 1977. Virus-like particles in placentas from normal individuals and patients with systemic lupus erythematosus. J. Natl. Cancer Inst. 59: 1187-1192.
77. Kalter, S. S., R. J. Helmke, R. L. Heberling, M. Panigel, A. K. Fowler, J. E. Strickland, and A. Hellman. 1973. Brief communication: C-type particles in normal human placentas. J. Natl. Cancer Inst. 50: 1081-1084.
78. Vernon, M. L., J. M. McMahon, and J. J. Hackett. 1974. Additional evidence of type-C particles in human placentas. J. Natl. Cancer Inst. 52: 987-989.
79. Waterland, R. A., and R. L. Jirtle. 2003. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 23: 5293-5300.
80. Szpakowski, S., X. Sun, J. M. Lage, A. Dyer, J. Rubinstein, D. Kowalski, C. Sasaki, J. Costa, and P. M. Lizardi. 2009. Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene 448: 151-167.
81. Cegolon, L., C. Salata, E. Weiderpass, P. Vineis, G. Palù, and G. Mastrangelo. 2013. Human endogenous retroviruses and cancer prevention: evidence and prospects. BMC Cancer 13: 4.
82. Katoh, I., and S. I. Kurata. 2013. Association of Endogenous Retroviruses and Long Terminal Repeats with Human Disorders. Front. Oncol. 3: 234.
83. Schiavetti, F., J. Thonnard, D. Colau, T. Boon, and P. G. Coulie. 2002. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 62: 5510-5516.
84. Takahashi, Y., N. Harashima, S. Kajigaya, H. Yokoyama, E. Cherkasova, J. P. McCoy, K. Hanada, O. Mena, R. Kurlander, A. Tawab, et al. 2008. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. [Published erratum appears in 2008 J. Clin. Invest. 118: 1584.] J. Clin. Invest. 118: 1099-1109.
85. Malarkannan, S., T. Serwold, V. Nguyen, L. A. Sherman, and N. Shastri. 1996. The mouse mammary tumor virus env gene is the source of a CD8+ T-cell-stimulating peptide presented by a major histocompatibility complex class I molecule in a murine thymoma. Proc. Natl. Acad. Sci. USA 93: 13991-13996.
86. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93: 9730-9735.
87. Li, M., X. Huang, Z. Zhu, and E. Gorelik. 1999. Sequence and insertion sites of murine melanoma-associated retrovirus. J. Virol. 73: 9178-9186.
88. Pothlichet, J., M. Mangeney, and T. Heidmann. 2006. Mobility and integration sites of a murine C57BL/6 melanoma endogenous retrovirus involved in tumor progression in vivo. Int. J. Cancer 119: 1869-1877.
89. Delviks-Frankenberry, K., O. Cingöz, J. M. Coffin, and V. K. Pathak. 2012. Recombinant origin, contamination, and de-discovery of XMRV. Curr. Opin. Virol. 2: 499-507.
90. Dewannieux, M., D. Ribet, and T. Heidmann. 2010. Risks linked to endogenous retroviruses for vaccine production: a general overview. Biologicals 38: 366-370.